Filing Analysis
Serina Therapeutics entered into a Common Stock Purchase Agreement with Roth Principal Investments, LLC, allowing the company to sell up to $25,000,000 of newly issued common stock over a 36-month period. The agreement includes a registration rights component and utilizes a discounted VWAP-based pricing mechanism.
🚩 Red Flags
- Equity Dilution: The agreement allows for the issuance of significant new shares, which will dilute existing shareholders.
- Discounted Pricing: Selling shares at a 3-7% discount to VWAP is a common feature of 'death spiral' or highly dilutive financing structures used by micro-cap companies with limited cash runway.
- At-the-Market (ATM) style structure: The company has the discretion to sell shares at various times, which can create continuous downward pressure on the stock price.
📋 Key Facts
- Total potential equity raise: up to $25,000,000.
- Counterparty: Roth Principal Investments, LLC.
- Term: Up to 36 months from the 'Commencement Date'.
- Pricing: Shares are sold at a discount to VWAP (3% to 7% discount depending on the type of purchase and cumulative amount sold).
- Purchase types: Includes Market Open, Intraday, Pre-Market, and Post-Market purchases.
- Exchange Cap: Issuance is limited to 19.99% of outstanding shares unless stockholder approval is obtained or a specific 'Base Price' of $2.7695 is met.
Serina Therapeutics, Inc. filed an 8-K to announce its quarterly financial results for the period ending June 30, 2026. The filing serves as a formal notice of the earnings release issued on August 13, 2026.
📋 Key Facts
- The company announced financial results for the quarter ended June 30, 2026.
- The announcement was made via press release on August 13, 2026.
- The filing includes Exhibit 99.1 containing the full press release.
Serina Therapeutics, Inc. announced the appointment of Farrell Simon, Pharm. D., to its Board of Directors, effective July 22, 2026. Dr. Simon will also serve on the Audit and Compensation Committees.
📋 Key Facts
- Farrell Simon appointed to the Board of Directors effective July 22, 2026.
- Dr. Simon will serve as a member of both the Audit Committee and the Compensation Committee.
- Dr. Simon currently serves as Chief Commercial Officer at Trevi Therapeutics, Inc. (Nasdaq: TRVI).
- He has significant experience in commercial strategy and business development from Pfizer and Trevi Therapeutics.
- Compensation for his role will be governed by the Company’s Director Compensation Policy.
Serina Therapeutics held its 2026 Annual Meeting of Stockholders on June 17, 2026, resulting in the election of three directors and approval of several key proposals. Notably, stockholders approved a significant increase in authorized common stock from 40 million to 125 million shares.
🚩 Red Flags
- Massive increase in authorized share count (from 40M to 125M) provides significant headroom for future dilutive equity offerings.
📋 Key Facts
- Annual Meeting held on June 17, 2026; results reported via 8-K filed June 24, 2026.
- Authorized common stock increased from 40,000,000 to 125,000,000 shares (Proposal 2).
- Three directors elected: Gregory H. Bailey, M.D., Richard Marshall, CBE, M.D., Ph.D., and Jay Venkatesan, M.D.
- Approved amendment to the 2024 Equity Incentive Plan to increase available shares by 2,000,000 (Proposal 3).
- Stockholders approved conversion of Series A Preferred Stock into common stock (Proposal 4) and exercise of Private Placement Securities into common stock (Proposal 5).
- Ratification of Frazier & Deeter, LLC as independent auditors for fiscal year 2026 (Proposal 8).
Serina Therapeutics, Inc. announced its financial results for the fiscal quarter ended March 31, 2026. The disclosure was made through a press release furnished as an exhibit to the filing.
📋 Key Facts
- Financial results for the quarter ended March 31, 2026, were released on May 14, 2026.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- The press release is furnished as Exhibit 99.1 and is not considered 'filed' for purposes of Section 18 of the Exchange Act.
Serina Therapeutics announced the promotion of Dr. Srini Tenjarla to Chief Technology Officer and a significant salary increase for CEO Steve Ledger. Additionally, the company amended its bylaws to implement a Co-Chair board structure where each Co-Chair holds independent authority.
🚩 Red Flags
- Significant retroactive salary increase for the CEO dating back to September 2024 (approximately 19 months), resulting in a large immediate cash lump-sum payment.
- The introduction of a 'Co-Chair' structure where each chair can act independently is unusual and may lead to governance or coordination challenges.
📋 Key Facts
- Dr. Srini Tenjarla promoted to CTO of Serina (AL), Inc. with an annual base salary of $425,000, retroactive to March 15, 2026.
- CEO Steve Ledger's annual base salary increased to $500,000, retroactive to September 9, 2024.
- The CEO's retroactive pay was issued as a lump sum in April 2026 following the satisfaction of 'certain strategic goals'.
- Bylaws were amended on April 15, 2026, to allow for Co-Chairs of the Board of Directors with the power to act independently of one another.
Serina Therapeutics, Inc. announced its financial results for the fiscal year ended December 31, 2025. The disclosure was made through a press release furnished as an exhibit to the filing.
📋 Key Facts
- The filing was made on March 25, 2026, to report financial results for the year ended December 31, 2025.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- Serina Therapeutics is listed on the NYSE American under the ticker symbol SER.
- The filing was signed by Steve Ledger, the Chief Executive Officer.
Serina Therapeutics entered into a private placement agreement to raise up to $30 million, with an initial $15 million closed on March 20, 2026. The financing is led by Director Greg Bailey (representing largest shareholder Juvenescence), who has been appointed Co-Chairman of the Board as part of the transaction.
🚩 Red Flags
- Significant related-party transaction involving a director and the company's largest shareholder.
- Potential for substantial dilution through warrants and pre-funded warrants.
- Governance shift to a Co-Chairman structure and an additional investor-designated board seat.
- Requirement to hold stockholder meetings every 90 days if approval for the lead investor's shares is not initially obtained.
📋 Key Facts
- Initial $15.0 million funded on March 20, 2026; total potential raise up to $30.0 million through additional closings.
- Securities sold at $2.25 per share, including common stock and pre-funded warrants.
- Investors receive 50% warrant coverage with Redeemable Warrants exercisable at $5.00 per share.
- Lead investor Greg Bailey (Juvenescence) appointed Co-Chairman of the Board alongside current Executive Chairman Simba Gill.
- Company has the right to redeem warrants at $0.01 if stock hits $10.00 and specific clinical milestones for SER-252 Phase 1b are met.
- Amendment to the September 2025 Senior Unsecured Convertible Promissory Note removes further borrowing obligations.
- Issuance of shares to Dr. Bailey is subject to NYSE American stockholder approval.
Serina Therapeutics announced that the FDA has cleared its Investigational New Drug (IND) application for SER-252, intended for the treatment of advanced Parkinson’s disease. This clearance enables the company to begin regulatory and site-level preparations for a Phase 1b registrational clinical study.
📋 Key Facts
- FDA has cleared the IND application for SER-252.
- Target indication: Advanced Parkinson's disease.
- The next major milestone is a planned Phase 1b registrational clinical study.
- Announcement date: January 28, 2026.
Serina Therapeutics received a notification from NYSE American stating it is in non-compliance with minimum stockholders' equity requirements. As of September 30, 2025, the company reported $1.6 million in stockholders' equity, falling below the required threshold due to consecutive net losses.
🚩 Red Flags
- Delisting notice from NYSE American
- Failure to meet minimum stockholders' equity requirements
- History of net losses in three of the last four fiscal years
- Low equity position ($1.6M) relative to required thresholds
📋 Key Facts
- Received NYSE American notification on January 9, 2026.
- Non-compliance with Sections 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide regarding minimum stockholders' equity.
- Stockholders' equity was $1.6 million as of September 30, 2025.
- Company has reported losses in three of its four most recent fiscal years ended December 31, 2024.
- Deadline to submit a compliance plan is February 8, 2026.
- Cure period for regaining compliance extends until July 9, 2027.
Serina Therapeutics announced the submission of a complete response to an FDA clinical hold letter regarding its lead SER-252 program for advanced Parkinson's disease. The company is working to resolve regulatory hurdles to advance its primary therapeutic candidate.
🚩 Red Flags
- Existence of a prior FDA clinical hold (dated Nov 25, 2025) indicates significant regulatory friction for the lead asset.
📋 Key Facts
- Company submitted a complete response to the FDA on December 10, 2025.
- The submission addresses an FDA clinical hold letter dated November 25, 2025.
- The program in question is SER-252, targeting advanced Parkinson's disease.
Serina Therapeutics, Inc. filed an 8-K to announce the release of its financial results for the quarterly period ended September 30, 2025.
📋 Key Facts
- The filing was made on November 13, 2025.
- The report pertains to Item 2.02 (Results of Operations and Financial Condition).
- Financial results were issued via a press release dated November 13, 2025 (Exhibit 99.1).
Serina Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders on November 7, 2025. The meeting resulted in the election of two directors and the ratification of auditors, alongside stockholder approval for a convertible note and warrants proposal.
🚩 Red Flags
- Approval of convertible note/warrants can lead to future dilution of existing shareholders.
📋 Key Facts
- Annual Meeting held on November 7, 2025.
- Steve Ledger and Karen J. Wilson were elected to the Board of Directors until the 2028 Annual Meeting.
- Frazier & Deeter, LLC was ratified as independent auditors for the 2025 fiscal year.
- Stockholders approved the issuance of common stock related to the exercise of a Convertible Note and Warrants proposal.
Serina Therapeutics announced that the FDA has placed a clinical hold on its Investigational New Drug (IND) application for SER-252, which is the company's lead development program targeting advanced Parkinson’s disease.
🚩 Red Flags
- Clinical hold on a lead development program significantly impacts the company's primary value driver.
- Regulatory setbacks of this nature often lead to increased cash burn due to delays and required remedial actions.
📋 Key Facts
- FDA has placed a clinical hold on the IND application for SER-252.
- SER-252 is identified as the Company's lead development program.
- The program targets advanced Parkinson’s disease.
- The announcement was made via press release on November 3, 2025.
Serina Therapeutics announced the receipt of the first $5 million installment from a previously announced unsecured convertible note dated September 9, 2025. This represents an incremental funding event under an existing debt arrangement.
🚩 Red Flags
- Use of unsecured convertible notes often indicates limited access to traditional senior debt or equity markets.
- Convertible notes typically lead to future dilution for existing shareholders upon conversion.
📋 Key Facts
- Received $5 million in funding on October 6, 2025.
- Funding is part of an unsecured convertible note dated September 9, 2025.
- The filing references a previous 8-K filed on September 15, 2025, regarding the same debt instrument.
Serina Therapeutics entered into a $20 million unsecured convertible note agreement with Board Member Dr. Gregory H. Bailey, structured in five tranches tied to clinical and operational milestones. The transaction involves significant potential dilution through warrants and conversion rights at a fixed price.
🚩 Red Flags
- Related-party transaction: The lender is a member of the Company's Board of Directors (Dr. Gregory H. Bailey).
- Potential for significant dilution via convertible notes and warrants.
- Milestone-based funding structure suggests the company may be facing liquidity constraints, as tranches are tied to clinical progress rather than immediate cash needs.
- The note includes a 'deficiency' clause requiring the company to draw funds if it lacks sufficient cash to reach the next milestone.
📋 Key Facts
- Aggregate principal amount of up to $20 million via an unsecured convertible note.
- Funding is released in five tranches tied to specific clinical milestones (e.g., patient enrollment and dosing in SER-252-1b study) through April 30, 2026.
- Interest rate of 10% per annum, payable quarterly after the first anniversary.
- Conversion price set at $5.18 per share; warrants issued with an exercise price of $5.44 per share.
- The note includes a mandatory cash repayment clause in the event of a liquidity event or change of control.
- Transactions were approved by a Special Committee of independent and disinterested directors.
Serina Therapeutics, Inc. filed an 8-K to furnish a press release dated September 9, 2025, pursuant to Regulation FD. The filing does not contain specific financial data or material event details in the text provided.
📋 Key Facts
- Filing date: September 9, 2025
- Reported event date: September 8, 2025
- The information is being furnished under Item 7.01 (Regulation FD Disclosure), not filed.
- Exhibit 99.1 contains the actual press release content.
Serina Therapeutics announced that following a Type B meeting, the FDA provided feedback supporting the advancement of SER-252 (POZ-apomorphine) into registrational clinical studies for advanced Parkinson’s disease via the 505(b)(2) NDA pathway.
📋 Key Facts
- FDA Type B meeting held prior to August 25, 2025.
- FDA feedback supports a registrational clinical study program for SER-252 (POZ-apomorphine).
- The regulatory pathway identified is the 505(b)(2) NDA pathway for advanced Parkinson's disease.
Serina Therapeutics amended its Bylaws to include safe harbor procedures for transactions involving interested directors or officers and expanded the forum selection clause in its Certificate of Incorporation.
🚩 Red Flags
- Expansion of forum selection clauses can sometimes be used to limit shareholder litigation, though it is a standard corporate governance practice.
📋 Key Facts
- The Board of Directors approved amendments to the Company's Amended and Restated Bylaws on August 18, 2025.
- Amendments include safe harbor procedures for transactions involving directors, officers, or controlling stockholders that might involve conflicts of interest.
- The forum selection clause in Section 9.2 of the Certificate of Incorporation was expanded to cover stockholder claims related to corporate business and affairs.
Serina Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2025. The filing serves as a formal notice that a press release containing these results was issued on August 11, 2025.
📋 Key Facts
- Report date: August 11, 2025
- Reporting period: Quarter ended June 30, 2025
- The filing includes a press release as Exhibit 99.1 containing financial results.
Serina Therapeutics issued an 8-K to provide updates regarding its product candidate SER-270 and announce CEO Steve Ledger's participation in the BTIG Virtual Biotechnology Conference. The filing includes a presentation and press release under Regulation FD.
📋 Key Facts
- Company announced advancement of SER-270 (POZ-conjugated VMAT2 inhibitor) for tardive dyskinesia treatment.
- CEO Steve Ledger to participate in the BTIG Virtual Biotechnology Conference on July 29, 2025.
- The filing includes a presentation (Exhibit 99.1) and a press release (Exhibit 99.2).
- Information is furnished under Regulation FD, meaning it is not considered material or complete for investment decisions by the company.
Serina Therapeutics announced the date for its 2025 annual meeting of stockholders and established deadlines for stockholder proposals and director nominations. The company also issued a press release under Regulation FD.
📋 Key Facts
- The 2025 Annual Meeting of Stockholders is scheduled for November 7, 2025.
- The deadline for Rule 14a-8 stockholder proposals is August 15, 2025, at 5:00 p.m. CT.
- Director nominations and non-Rule 14a-8 proposals must be received between July 10, 2025, and August 9, 2025.
- The filing includes a press release issued on July 1, 2025, under Regulation FD.
Serina Therapeutics announced a change in its Board of Directors, appointing Dr. Stephen Brannan and the departure of Remy Gross. Additionally, the company filed a Certificate of Correction to clarify conversion price adjustment terms for Series A Convertible Preferred Stock.
🚩 Red Flags
- Amendment to preferred stock terms (Certificate of Correction) may indicate previous clerical errors in capital structure documentation.
📋 Key Facts
- Dr. Stephen Brannan appointed to the Board of Directors and Compensation Committee effective May 22, 2025.
- Dr. Brannan previously served as CMO at Karuna Therapeutics (acquired by Bristol Myers Squibb for $14B).
- Remy Gross departed from the Board of Directors effective May 22, 2025; departure is not due to a disagreement with the company.
- Filed a Certificate of Correction in Delaware to clarify that the Series A Convertible Preferred Stock conversion price ($5.18) is subject to adjustments under Section 9(b).
Serina Therapeutics, Inc. filed an 8-K to announce the release of its financial results for the three months ended March 31, 2025.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Reporting period: Three months ended March 31, 2025.
- Date of report/event: May 8, 2025.
Serina Therapeutics entered into an 'at the market' (ATM) sales agreement with JonesTrading Institutional Services LLC to facilitate the sale of common stock up to a maximum aggregate price of $13,270,500.
🚩 Red Flags
- Potential dilution for existing shareholders through the issuance of new common stock.
- ATM offerings are often used by micro-cap biotech companies to bolster cash runways, which can signal immediate liquidity needs.
📋 Key Facts
- Entered into Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC on April 25, 2025.
- Maximum aggregate offering price: $13,270,500.
- Commission rate to agent (Jones): up to 3.0% of gross sales proceeds.
- The company will reimburse Jones for legal expenses up to a maximum of $50,000.
- Sales will be conducted via an existing Form S-3 registration statement.
Serina Therapeutics, Inc. filed an 8-K to furnish a presentation and press release regarding the Chief Development Officer's appearance at the LNP Formulation & Process Development Summit.
📋 Key Facts
- Dr. Randall Moreadith (Chief Development Officer) is presenting at the LNP Formulation & Process Development Summit in Boston, MA on April 15, 2025.
- The filing includes a presentation (Exhibit 99.1) and a press release (Exhibit 99.2).
- Information was furnished pursuant to Regulation FD.
Serina Therapeutics entered into a Securities Purchase Agreement to conduct a private placement of Series A Convertible Preferred Stock. The company raised approximately $5 million by issuing 962,250 shares at a price of $5.18 per share.
🚩 Red Flags
- Dilutive potential: The Series A Preferred Stock is convertible into common stock, which may lead to significant dilution for existing shareholders.
- Dividend obligation: An 8.0% cumulative dividend must be paid in preference over common stock, increasing the company's capital obligations.
📋 Key Facts
- Private placement of 962,250 shares of Series A Convertible Preferred Stock.
- Aggregate gross proceeds: approximately $5 million.
- Issue price: $5.18 per share.
- Conversion price: Initially $5.18 per share.
- Series A Preferred Stock carries an 8.0% annual cumulative dividend, payable in kind on March 31st each year.
- Mandatory conversion triggers include the stock price exceeding 2x the conversion price for 10 out of 20 trading days or a subsequent $20 million capital raise.
Serina Therapeutics announced that CEO Steve Ledger will present at the Jones Healthcare and Technology Innovation Conference on April 9, 2025. The filing is a routine Regulation FD disclosure regarding upcoming investor presentation materials.
📋 Key Facts
- CEO Steve Ledger to present at the Jones Healthcare and Technology Innovation Conference in Las Vegas, NV.
- Presentation date: April 9, 2025, at 3:00 p.m. PDT.
- The filing includes a press release (Exhibit 99.2) and presentation materials (Exhibit 99.1).
- Information is furnished under Regulation FD rather than filed.
Serina Therapeutics, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2024.
📋 Key Facts
- The filing was made on March 24, 2025.
- The report covers financial results for the year ended December 31, 2024.
- A press release containing the detailed results was issued as Exhibit 99.1.
Serina Therapeutics, Inc. filed an 8-K to announce that Chief Development Officer Randall Moreadith, M.D., Ph.D., will present at the American Chemistry Society Spring 2025 Meeting and Expo.
📋 Key Facts
- Chief Development Officer Randall Moreadith, M.D., Ph.D. is presenting at the American Chemistry Society Spring 2025 Meeting and Expo in San Diego, CA.
- The presentation materials are furnished under Item 7.01 pursuant to Regulation FD.
- Filing date: March 24, 2025.
Serina Therapeutics announced a leadership transition on its Board of Directors, appointing Dr. Jay Venkatesan as a new Director and Audit Committee Chair, while J. Milton Harris, Ph.D. is stepping down from the Board to become Director Emeritus and SAB Chair.
🚩 Red Flags
- None identified; Dr. Harris's departure is explicitly stated to be not due to any disagreement with the Company.
📋 Key Facts
- Dr. Jay Venkatesan appointed to the Board effective February 12, 2025.
- Dr. Venkatesan will serve as Audit Committee Chair and a member of the Nominating and Corporate Governance Committee.
- J. Milton Harris, Ph.D. departed the Board effective February 11, 2025.
- Dr. Harris will transition to Director Emeritus and Chair of the Scientific Advisory Board (SAB).
- Dr. Venkatesan previously served as CEO of Angion Biomedica and co-founded Alpine Immune Sciences (acquired by Vertex Pharmaceuticals for $4.9B).
Serina Therapeutics filed an 8-K to furnish a press release pursuant to Regulation FD. The filing does not contain specific material financial updates or structural changes in the text provided.
📋 Key Facts
- Filing date: February 3, 2025
- The report is intended to satisfy Regulation FD disclosure requirements via Exhibit 99.1
- Information is being furnished, not filed, meaning it will not be incorporated by reference into registration statements unless specifically identified.
Serina Therapeutics announced a leadership transition on its Board of Directors, involving the appointment of Karen J. Wilson and the departure of Steven Mintz. Ms. Wilson will assume roles as Compensation Committee Chair and Audit Committee member.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Karen J. Wilson appointed to the Board of Directors effective January 14, 2025.
- Ms. Wilson appointed as Compensation Committee Chair and a member of the Audit Committee.
- Steven Mintz departed from the Board of Directors; he stated his departure is not due to any disagreement with the Company.
- Remy Gross will replace Steven Mintz as the chair of the Audit Committee.
- Karen J. Wilson brings extensive life sciences finance experience, including former SVP of Finance at Jazz Pharmaceuticals plc.
Serina Therapeutics released an investor presentation containing preliminary, unaudited financial information as of December 31, 2024. The company notes that these figures are subject to change pending the completion of year-end audit procedures.
🚩 Red Flags
- Information is unaudited and preliminary; final audited figures may differ significantly.
📋 Key Facts
- Released investor presentation dated January 6, 2025.
- Presentation includes preliminary and unaudited financial information as of December 31, 2024.
- The company is currently undergoing its normal financial close and audit procedures for the fiscal year ended Dec 31, 2024.
Serina Therapeutics has entered into a Stock Purchase Agreement with its largest shareholder, Juvenescence (UK) Limited, resulting in the sale of UniverXome Bioengineering, Inc. In exchange for the company's subsidiary, Juvenescence assumed approximately $11.2 million of secured debt and provided a nominal cash payment.
🚩 Red Flags
- Related-party transaction: The buyer (Juvenescence) is the company's largest common stock holder and has two designees on the Board of Directors.
- Significant asset disposition: The company is divesting its primary operating subsidiaries (ReCyte and Reverse Bio) to settle/transfer debt.
- Debt assumption: The transaction is primarily a mechanism for transferring $11.2 million in secured debt from the company's subsidiary to the majority shareholder.
📋 Key Facts
- Transaction Date: December 23, 2024
- Buyer: JuvVentures (UK) Limited (Juvenescence)
- Asset Sold: UniverXome Bioengineering, Inc. (including subsidiaries ReCyte Therapeutics and Reverse Bioengineering)
- Consideration: Assumption of ~$11.2 million in secured debt by Juvenescence plus nominal cash
- The assets being sold include intellectual property, patents, biological materials, and equipment related to stem cell-derived progenitor cells and cellular reprogramming technology.
Serina Therapeutics held its 2024 Annual Meeting of Stockholders on December 13, 2024. The filing reports the successful election of three directors and the approval of an amendment to the company's 2024 Equity Incentive Plan.
📋 Key Facts
- Annual Meeting held on December 13, 2024.
- Three nominees (Balkrishan 'Simba' Gill, Remy Gross, and Steven Mintz) were elected to the Board of Directors until the 2027 Annual Meeting.
- Stockholders approved an amendment to the 2024 Equity Incentive Plan, increasing reserved shares by 950,000 to a total of 2,675,000.
- The Amendment includes an automatic annual increase in shares reserved for issuance (5% of outstanding common stock) from fiscal year 2026 through 2034.
- Stockholders ratified the appointment of Frazier & Deeter, LLC as independent auditors for the 2024 fiscal year.
Serina Therapeutics, Inc. issued an 8-K to announce that its Chief Development Officer, Randall Moreadith, MD, PhD, will present at the 3rd Annual LNP Immunogenicity & Toxicity Summit on December 11, 2024.
📋 Key Facts
- Dr. Randall Moreadith (Chief Development Officer) is presenting at the 3rd Annual LNP Immunogenicity & Toxicity Summit in Boston, MA.
- The presentation materials were furnished under Item 7.01 pursuant to Regulation FD.
- The filing includes a press release and the presentation as exhibits.
Serina Therapeutics entered into a $10 million equity agreement with its largest shareholder, Juvenescence Limited, involving the sale of 1,000,000 shares and replacement warrants. The transaction is structured in two tranches to provide immediate liquidity and involves related-party board designees.
🚩 Red Flags
- Related-party transaction: Juvenescence is the largest shareholder and has appointed two board designees (Greg Bailey and Richard Marshall).
- Significant dilution potential from the issuance of 1,000,000 shares and 755,728 warrants.
- Dependency on a single large investor for significant capital infusion.
📋 Key Facts
- Total aggregate investment: $10 million via two $5 million tranches.
- First tranche of 500,000 shares closed on November 27, 2024.
- Second tranche of 500,000 shares to close by January 31, 2025; secured by 122,136 pledged shares from Juvenescence.
- Issuance of 'Replacement Incentive Warrants' for 755,728 shares at an exercise price of $18.00 per share (expiring March 26, 2028).
- The deal involves the surrender and cancellation of previously issued Post-Merger Warrants.
- Company must file a registration statement for resale by April 2, 2025.
Serina Therapeutics, Inc. filed an 8-K to announce its financial results for the three and nine months ended September 30, 2024. The filing serves as a formal notice that a press release containing these results was issued on November 12, 2024.
📋 Key Facts
- Reporting period: Three and nine months ended September 30, 2024.
- Report date: November 12, 2024.
- The filing includes a press release as Exhibit 99.1 containing the financial results.
Serina Therapeutics, Inc. filed an 8-K to announce the participation of its Chief Development Officer in the 14th Annual Injectables Summit. The filing includes a presentation and a press release furnished under Regulation FD.
📋 Key Facts
- Dr. Randall Moreadith (Chief Development Officer) participated in the 14th Annual Injectables Summit on October 2, 2024.
- The company provided a presentation (Exhibit 99.1) and a press release (Exhibit 99.2) regarding its participation.
- Information was furnished under Regulation FD rather than filed.
Serina Therapeutics, Inc. has appointed Steven Ledger as its permanent Chief Executive Officer, effective September 9, 2024. Mr. Ledger transitions from his role as Interim CEO to the permanent position under a new employment agreement.
📋 Key Facts
- Steven Ledger appointed as CEO effective September 9, 2024.
- Mr. Ledger has served as Interim CEO and Class II Director since March 2024.
- Annual base salary is set at $450,000, with an automatic increase to $500,000.
- Incentive compensation opportunity of up to 50% of base salary.
- Grant of 501,851 stock options under the 2024 Equity Incentive Plan; 75% vest over time (starting March 9, 2025) and 25% based on strategic goals.
- Employment agreement includes a 2-year non-compete and 18-month non-solicitation clause.
Serina Therapeutics announced that Interim CEO Steve Ledger will participate in the H.C. Wainwright 26th Annual Global Investment Conference on September 11, 2024.
📋 Key Facts
- Interim CEO Steve Ledger to present at the H.C. Wainwright 26th Annual Global Investment Conference.
- Conference date: September 11, 2024.
- The disclosure is made pursuant to Regulation FD (Item 7.01).
Serina Therapeutics announced the departure of its Interim CFO and CAO, Andrea Park, effective August 15, 2024. The company has appointed Gregory S. Curhan as a non-employee consultant in the role of CFO, effective August 16, 2024.
🚩 Red Flags
- Replacement of the Interim CFO with a non-employee consultant rather than a full-time executive may indicate transitional instability or cost-cutting measures.
- The acceleration clause on stock options tied to a '$60 million equity transaction' suggests potential upcoming financing needs or restructuring.
📋 Key Facts
- Interim CFO and CAO Andrea Park's employment ends effective August 15, 2024.
- Gregory S. Curhan appointed as CFO in a non-employee consultant role, effective August 16, 2024.
- Curhan will be compensated at a rate of $650 per hour via FLG Partners.
- Curhan awarded an option to purchase 250,000 shares of Common Stock, vesting monthly over 48 months.
- Option vesting accelerates upon a change in control or completion of a $60 million equity transaction.
Serina Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter and six months ended June 30, 2024.
📋 Key Facts
- The filing was made on August 9, 2024.
- The report covers financial results for the quarter and six months ending June 30, 2024.
- The company is an emerging growth company.
- Interim CFO Andrea Park signed the report.
Serina Therapeutics, Inc. filed an 8-K to announce that its Chief Development Officer, Dr. Randall Moreadith, will present at the 4th Annual mRNA-Based Therapeutics Summit in Boston.
📋 Key Facts
- Dr. Randall Moreadith (Chief Development Officer) is participating in the 4th Annual mRNA-Based Therapeutics Summit from July 29 to July 31, 2024.
- The company furnished a presentation (Exhibit 99.1) and a press release (Exhibit 99.2) under Regulation FD.
- The filing is for the purpose of disseminating information via Item 7.01.
Serina Therapeutics announced the hiring of Dr. Srini Tenjarla as Senior Vice President, CMC & Formulation, effective July 15, 2024. He brings significant industry experience from Takeda Pharmaceuticals and Shire Pharmaceuticals to oversee the company's pipeline development activities.
📋 Key Facts
- Dr. Srini Tenjarla appointed as Senior Vice President, CMC & Formulation.
- Employment commenced on July 15, 2024.
- Tenjarla previously served as VP and Head of Drug Product Development at Takeda Pharmaceuticals.
- Tenjarla held leadership roles at Shire Pharmaceuticals prior to Takeda.
Serina Therapeutics announced the retirement of its Chief Operating Officer, Tacey Viegas, effective July 15, 2024. The departure includes a separation agreement and a subsequent consulting arrangement to assist with various projects.
🚩 Red Flags
- Executive turnover in a micro-cap biotech environment can sometimes signal internal shifts, though this is framed as retirement.
📋 Key Facts
- Tacey Viegas will retire as COO on July 15, 2024.
- Separation Agreement: Dr. Viegas will receive base salary plus $1,000 per month for 12 months post-retirement, subject to a general release of claims.
- Consulting Agreement: Effective July 14, 2024, Dr. Viegas will serve as a consultant on various projects with no additional compensation beyond the terms mentioned.
- Stock Options: Dr. Viegas holds options for 341,889 shares at an exercise price of $0.06 per share; the consulting agreement extends the term of these options.
Serina Therapeutics announced that Juvenescence Limited has exercised a portion of its Post-Merger Warrants, resulting in the issuance of 377,865 shares at an exercise price of $13.20 per share.
🚩 Red Flags
- Warrant dilution: The issuance of shares via warrant exercise dilutes existing shareholders.
- Structured dilution schedule: The company is subject to a mandatory multi-year dilution schedule (remaining tranches due in late 2024 and mid-2025).
📋 Key Facts
- Juvenescence Limited purchased 377,865 shares of Common Stock for a total price of $4,987,818.
- The exercise price was $13.20 per share.
- Upon exercise, Juvenescence also received incentive warrants to purchase an additional 377,865 shares at an exercise price of $18.00 per share, expiring March 26, 2028.
- This represents the first third of a three-part warrant exercise obligation under a Side Letter.
- The second third must be exercised by November 30, 2024, and the final third by June 30, 2025.
Serina Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2024. The filing also notes a completed merger transaction where AgeX Therapeutics, Inc. merged into Serina via a reverse takeover structure.
🚩 Red Flags
- Complexity of recent merger/reorganization structure (AgeX/Serina).
📋 Key Facts
- The Company reported financial results for the quarter ended March 31, 2024 on May 14, 2024.
- A merger transaction was completed on March 26, 2024, involving AgeX Therapeutics, Inc., Canaria Transaction Corporation, and Serina Therapeutics, Inc.
- Following the merger, AgeX Therapeutics, Inc. changed its name to Serina Therapeutics, Inc.
- The Company is classified as an emerging growth company.
Serina Therapeutics announced the dismissal of its previous auditor, WithumSmith+Brown, PC, and the appointment of Frazier & Deeter, LLC as its new independent registered public accounting firm. This change follows a recent merger where AgeX Therapeutics, Inc. became Serina Therapeutics, Inc.
🚩 Red Flags
- Going concern language in previous audit reports (FY 2022, FY 2023) regarding the company's ability to continue operations.
- Auditor change following a corporate merger/reorganization.
📋 Key Facts
- Frazier & Deeter, LLC has been engaged as the independent auditor for the fiscal year ending December 31, 2024.
- WithumSmith+Brown, PC was dismissed and replaced by Frazier & Deeter.
- The company completed a merger on March 26, 2024, where AgeX Therapeutics, Inc. became Serina Therapeutics, Inc.
- The previous auditor (Withum) reported substantial doubt about the Company's ability to continue as a going concern for fiscal years 2023 and 2022.
Serina Therapeutics, Inc. announced the appointment of Simba Gill, Ph.D., as the Company’s Chairman of the Board of Directors, effective April 12, 2024.
📋 Key Facts
- Simba Gill, Ph.D. appointed as Executive Chairman of the Board.
- Effective date of appointment: April 12, 2024.
- Compensation includes an annual cash fee of $300,000.
- Grant of 295,300 options to purchase Common Stock under the 2024 Equity Incentive Plan.
- Agreement includes a five-year post-termination non-compete and non-solicitation covenant.
AgeX Therapeutics, Inc. completed a reverse merger with Serina Therapeutics, Inc., resulting in a name change to Serina Therapeutics, Inc. and a shift in business focus to Serina's clinical-stage drug candidates. The transaction involved significant restructuring of debt and asset transfers to subsidiaries.
🚩 Red Flags
- Significant debt restructuring: $9.3M principal + fees owed to Juvenescence Limited via the 2022 Convertible Note.
- Complex corporate restructuring involving multiple subsidiaries (UniverXome, Reverse Bio, ReCyte) and asset transfers.
- High concentration of ownership in former Serina shareholders (75%).
- The company is a clinical-stage biotech, implying high burn rate and significant capital requirements.
📋 Key Facts
- Completed merger on March 26, 2024; Serina became a wholly owned subsidiary of AgeX.
- Company name changed from AgeX Therapeutics, Inc. to Serina Therapeutics, Inc.; ticker changed from AGE to SER.
- The transaction was treated as a reverse recapitalization under US GAAP.
- AgeX drew an additional $2.4 million from its 2022 Convertible Note with Juvenescence Limited, bringing the total principal to $9.3 million plus ~$561k in fees.
- UniverXome Bioengineering, Inc. assumed all rights and obligations of the 2022 and 2023 Convertible Notes from AgeX.
- AgeX transferred various assets (patents, IP, biological materials, equipment) to UniverXome via an Asset Contribution Agreement.
- Post-merger ownership: Prior Serina equityholders own ~75%; prior AgeX equityholders own ~25% on a fully diluted basis.
- The merger resulted in approximately 10.1 million shares of common stock outstanding (fully diluted, excluding warrants).
AgeX Therapeutics, Inc. filed an 8-K to announce its financial results for the fourth quarter and fiscal year ended December 31, 2023. The filing serves as a formal notice of the release of earnings data via press release.
📋 Key Facts
- Report date: March 22, 2024
- Reporting period: Fourth quarter and fiscal year ended December 31, 2023
- The company is an emerging growth company
- Financial results were issued via press release (Exhibit 99.1)
AgeX Therapeutics, Inc. has completed a 1-for-35.17 reverse stock split following stockholder approval at a special meeting. This action is part of a larger reorganization and merger with Serina Therapeutics, Inc., which is expected to close on March 26, 2024.
🚩 Red Flags
- Reverse stock split (1-for-35.17) is a significant red flag often used to maintain exchange listing requirements.
- Significant dilution: The merger involves issuing shares representing more than 20% of AgeX common stock outstanding.
📋 Key Facts
- Reverse stock split ratio: 1-for-35.17 effective March 14, 2024.
- Stockholders approved the merger with Serina Therapeutics, Inc., resulting in a change of control.
- The combined company will be renamed 'Serina Therapeutics, Inc.' and trade under ticker 'SER' on NYSE American starting March 27, 2024.
- Merger completion is anticipated for March 26, 2024.
- Stockholders approved an amendment to the charter allowing for the issuance of shares representing >20% of outstanding stock as part of the merger.
AgeX Therapeutics announced a significant restructuring involving a merger with Serina Therapeutics, which includes a proposed reverse stock split and the issuance of a warrant dividend. Additionally, the company drew $500,000 from an existing secured convertible promissory note.
🚩 Red Flags
- Proposed reverse stock split (often used to maintain exchange listing requirements).
- Upcoming debt repayment obligation of $500,000 due May 9, 2024.
- Issuance of warrants as part of a dividend/merger structure can lead to significant future dilution.
📋 Key Facts
- Drew $500,000 from an Amended and Restated Secured Convertible Promissory Note with Juvenescence Limited on March 5, 2024.
- The repayment date for the drawn principal is May 9, 2024.
- Proposed merger with Serina Therapeutics Inc. via a merger sub (Canaria Transaction Corporation).
- Board declared a warrant dividend: 3 warrants (Post-Merger Warrants) for every 5 shares of common stock held as of March 18, 2024.
- A reverse stock split is proposed to be effective on or about March 14, 2024, with trading on a post-split basis starting March 15, 2024.
- Post-Merger Warrants have an exercise price of $13.20 and expire July 31, 2025.
- Incentive Warrants have an exercise price of $18.00 and expire on the four-year anniversary of the merger closing.
AgeX Therapeutics entered into a sixth amendment to its Secured Convertible Promissory Note with Juvenescence Limited, extending the repayment deadline to May 9, 2024. Additionally, the company drew $500,000 from this existing credit facility on February 13, 2024.
🚩 Red Flags
- High frequency of amendments (Sixth Amendment) suggests ongoing restructuring or difficulty meeting original terms.
- Imminent repayment deadline (May 9, 2024) creates significant liquidity pressure.
- Reliance on convertible debt from a single entity (Juvenescence Limited) indicates potential dilution risk for existing shareholders.
📋 Key Facts
- Executed Sixth Amendment to Amended and Restated Convertible Promissory Note with Juvenescence Limited on February 9, 2024.
- Repayment Date for the Secured Note extended to May 9, 2024.
- Drew $500,000 from available credit under the Secured Note on February 13, 2024.
- The note is a 'Secured Convertible Promissory Note' originally dated February 9, 2023.
AgeX Therapeutics announced a change in control as Juvenescence Limited now holds 75.6% of common stock following a massive conversion of preferred and common shares. This transaction also involved a $500,000 debt draw from the same related party.
🚩 Red Flags
- Change in control resulting in a majority stakeholder (Juvenescence) holding 75.6% of voting power.
- Related-party debt draw: $500,000 drawn from an insider/controlling party with a very short repayment window (Feb 14, 2024).
- Potential dilution and governance shifts as the company transitions to 'controlled company' status.
📋 Key Facts
- Juvenescence (via JuvVentures) acquired 29,388,888 shares through automatic conversion of Series A and B Preferred Stock and Common Stock.
- Post-conversion, Juvenescence holds 66,447,499 shares, representing 75.6% of AgeX's total outstanding common stock.
- AgeX drew $500,000 from its Secured Convertible Promissory Note with Juvenescence on February 1, 2024.
- The repayment date for the $500,000 note is February 14, 2024.
- The company expects to qualify as a 'controlled company' under NYSE American rules due to this change in control.
- A merger with Serina Therapeutics is contemplated; post-merger, Serina equity holders are expected to own ~75% of the combined entity.
AgeX Therapeutics, Inc. has drawn $500,000 from its existing Secured Convertible Promissory Note with Juvenescence Limited. The repayment date for this obligation is set for February 14, 2024.
🚩 Red Flags
- Extremely short repayment window (less than one month from draw date).
- Use of convertible debt suggests potential dilution for existing shareholders.
- Secured nature of the note implies creditors have priority over equity holders in liquidation.
📋 Key Facts
- Drew $500,000 of available credit under the Amended and Restated Secured Convertible Promissory Note on January 16, 2024.
- The counterparty to the note is Juvenescence Limited.
- Repayment date for the outstanding principal balance is February 14, 2024.
AgeX Therapeutics, Inc. announced the appointment of Steven Mintz to its Board of Directors effective January 8, 2024. Mr. Mintz will serve on the Audit, Compensation, and Nominating and Corporate Governance Committees.
📋 Key Facts
- Appointment date: January 8, 2024
- Board size increased to four directors
- Steven Mintz appointed to Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee
- Compensation includes $34,331 in cash fees and 63,756 stock options for 2024 service
- Additional $9,809 cash fee specifically for serving as Chair of the Audit Committee
- Mr. Mintz is currently a director at Portage Biotech, Inc.
AgeX Therapeutics drew $500,000 from an existing Secured Convertible Promissory Note with Juvenescence Limited on January 3, 2024. The repayment date for this obligation is imminent, set for February 14, 2024.
🚩 Red Flags
- Imminent repayment obligation (February 14, 2024) creates significant short-term liquidity pressure.
- The use of a 'Secured' note suggests the lender has priority claim on assets in case of default.
- High frequency of debt draws/repayments often indicates tight cash runway for micro-cap biotech firms.
📋 Key Facts
- Drew $500,000 from the Amended and Restated Secured Convertible Promissory Note.
- The counterparty to the note is Juvenescence Limited.
- Repayment date for the outstanding principal balance is February 14, 2024.
- Filing date: January 5, 2024; Event date: January 3, 2024.